Actively Recruiting
Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)
Led by University of Aarhus · Updated on 2022-08-12
100
Participants Needed
2
Research Sites
308 weeks
Total Duration
On this page
Sponsors
U
University of Aarhus
Lead Sponsor
A
Aarhus University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Up to 40% of patients with PBC have an inadequate response to standard treatment with UDCA, hence bezafibrate, a PPAR-agonist is being introduced as add-on therapy in these patients. sCD163, fibrosis markers and bile acid composition are of special interest in PBC. In this study, the investigators will investigate how treatment with bezafibrate influence levels of macrophage activation markers and fibrosis markers as well as bile acid composition in patients offered bezafibrate as add-on therapy to UDCA.
CONDITIONS
Official Title
Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- PBC patient offered bezafibrate treatment
You will not qualify if you...
- Patient age under 18
- Life expectancy less than 6 months
- Known cancer
- Planned liver transplantation within 6 months
- Other liver disease (viral, autoimmune, alcohol, NAFLD/NASH)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark
Aarhus N, Central Jutland, Denmark, 8200
Actively Recruiting
2
Department of Medicine, Gastrounit Medical division
Hvidovre, Denmark, 2650
Actively Recruiting
Research Team
H
Henning Grønbæk, Prof, MD
CONTACT
L
Lars Bossen, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here